Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing Different FVIII Dose and Frequency in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study): a Multicenter Open-label Non-randomized Clinical Trial

NCT06864975 is registered in ClinicalTrials.gov with Runhui WU as lead sponsor.

NCT NCT06864975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06864975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing Different FVIII Dose and Frequency in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study): a Multicenter Open-label Non-randomized Clinical Trial
Lead sponsor
Runhui WU
Phase
Phase 4
Overall status
Recruiting
Start date
March 1, 2025
Completion date
June 21, 2028
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a with inhibitor